PI Industries reported its financial results for the first quarter of FY27, with revenue reaching ₹17,023 million and EBITDA at 22%. The company highlighted progress in its strategic initiatives, including advancements in its Agchem, Pharma, and Biologicals businesses. Key product developments, such as the Pioxaniliprole insecticide, are progressing towards commercial launch, reinforcing the company’s innovation pipeline and long-term growth strategy.
PI Industries Reports Q1 FY27 Financial Performance
PI Industries announced its financial results for the first quarter of FY27, ending June 30, 2026. The company reported a revenue of ₹17,023 million, accompanied by a healthy gross margin of 57% and an EBITDA margin of 22%. This performance reflects the company’s steady transition towards a growth trajectory amidst prevailing market conditions.
Strategic Initiatives and Business Updates
The management provided updates on key business segments. The Agchem export business continues to leverage its innovation and R&D capabilities, while the domestic Agri business focuses on differentiated crop protection solutions. The company is strategically investing in its integrated pharma platform, aiming to evolve into a fully integrated CRDMO. Furthermore, the global biologicals platform is gaining traction, with significant growth expected across various geographies.
Key Product Developments
PI Industries highlighted progress on its new product pipeline. The insecticide Pioxaniliprole, developed in-house, is in advanced stages for domestic market launch, awaiting regulatory approvals. The company also discussed its nematicide product, which offers a unique foliar application, registered in Brazil, Mexico, and the U.S. These developments underscore the company’s commitment to innovation and expansion into high-value adjacencies.
Financial Outlook and Investments
For FY27, PI Industries anticipates an improved performance over FY26, driven by the recovery in exports and the scaling up of its pharma and global biologicals businesses. The company is investing in its future growth platform, including new businesses and R&D initiatives, which contribute 3% to 4% of its revenue. Capital expenditure guidance for the full year is set between ₹700 crore to ₹800 crore.
The company also noted a reduction of 19 days in net working capital, releasing approximately ₹300 crore of cash. With a strong debt-free balance sheet and net cash of ₹38 billion, PI Industries is positioned for resilience and strategic investments.
Source: BSE
